Company Overview
Enlivex Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company based in Israel, focusing on developing therapeutic solutions to address critical medical needs through its specialized pipeline. The company functions within the broader Healthcare sector, specifically targeting the Biotechnology industry, where its activities center on advancing innovative treatments for complex conditions like organ dysfunction and failure caused by sepsis. In terms of scale, Enlivex Ltd. carries a market capitalization of $285.88M, while its annual revenue is currently reported as N/A, and the specific employee count is listed as N/A. The reported market cap of $285.88M indicates that the market values the company's potential in the biotechnology space significantly higher than its current financial output, suggesting that investors are pricing in the future success of its product pipeline rather than current operational performance. The absence of reported revenue and employee data further contextualizes the company's position as a pre-revenue or early-stage development entity, where valuation is driven primarily by intellectual property and clinical trial progress rather than established sales streams or workforce size.
Financial Health
The company reports a net income of $1.24B for the trailing twelve months (TTM), alongside an EBITDA of $-14,697,000, creating a distinct financial picture where the net income figure appears anomalously high relative to the significant negative operating cash metrics. This apparent gap between the reported net income of $1.24B and the negative EBITDA reveals a complex cost structure or potential non-operating income components that allow for profit recording despite substantial operational losses. The company's free cash flow stands at $-1,738,598,144, which indicates a severe cash burn rate that limits current financial flexibility and necessitates external capital raises to fund ongoing research and development activities. Analysis of the three primary margins shows a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, collectively indicating that the company is currently unable to generate profit from its core operations or sales activities. On the balance sheet, Enlivex holds $5.75M in cash against a debt obligation of $383,000, resulting in a debt-to-equity ratio of 0.02, which suggests a highly conservative leverage profile with minimal reliance on borrowed capital. The current ratio is reported at 193.24, a figure that indicates an extremely strong short-term liquidity position, meaning the company possesses more than enough current assets to cover its short-term liabilities many times over. Return on Equity is calculated at 126.2% while Return on Assets sits at -0.8%, metrics that reveal management has achieved a high return on the equity invested despite the negative return on the total asset base, likely due to the low absolute value of total assets relative to the reported equity.
Valuation Assessment
The trailing P/E ratio is listed as 0.05, while the forward P/E is negative at -1.54, implying that the market expects earnings to remain negative in the near future or that the current valuation is not supported by standard earnings multiples due to the company's unprofitable status. The price-to-book ratio is 0.15, indicating that the company is trading at a significant discount to its book value, which suggests the market is pricing in high risks associated with the clinical-stage nature of the business rather than a premium over assets. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -19.02, suggest that traditional multiple-based comparisons are not applicable, reinforcing that the stock price is decoupled from current sales or earnings performance. The 52-week high is $2.10 and the 52-week low is $0.66, meaning the current trading price sits somewhere within this range, reflecting the high volatility typical of small-cap biotechnology stocks without a beta value to quantify relative market sensitivity. The lack of a beta value prevents a direct comparison of price volatility relative to the broader market, but the wide spread between the 52-week high and low of $1.44 demonstrates the potential for significant price swings driven by clinical trial updates or regulatory decisions.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both reported as N/A, reflecting the company's status as a pre-revenue entity where historical growth rates cannot be calculated from existing sales data. Since the company does not pay dividends, with a dividend yield of N/A and a payout ratio of 0.0%, all available capital is reinvested into growth initiatives such as clinical trials and pipeline expansion rather than being distributed to shareholders. This reinvestment strategy is standard for clinical-stage biotechnology firms, where the primary objective is to advance products through development phases to potentially generate future revenue streams. The overall growth and income profile for Enlivex Ltd. is characterized by an absence of current income generation and reported growth metrics, with the entire financial narrative focused on the potential future value creation from the Allocetra product pipeline and other developments within its immunotherapy portfolio.